Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Lasso Regression for the Prediction of Intermediate Outcomes Related to Cardiovascular Disease Prevention Using the TRANSIT Quality Indicators.

Khanji C, Lalonde L, Bareil C, Lussier MT, Perreault S, Schnitzer ME.

Med Care. 2019 Jan;57(1):63-72. doi: 10.1097/MLR.0000000000001014.

PMID:
30439793
2.

Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.

Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, Mu Y, Hao C, Ji Q, Ran X, Su B, Zhuo H, Fox KA, Weber M, Zhang D; CCMR Advisory Board; CCMR-3B STUDY Investigators.

Am J Med. 2013 Oct;126(10):925.e11-22. doi: 10.1016/j.amjmed.2013.02.035. Epub 2013 Jun 27.

PMID:
23810406
3.

[The relationship between waist to stature ratio and hypertension, diabetes, and dyslipidemia in Qingdao].

Jing Y, Dong YH, Han T, Zhang L, Wang N, Zhu YM, Xu MH.

Zhonghua Nei Ke Za Zhi. 2012 Sep;51(9):683-6. Chinese.

PMID:
23158916
4.

Psychometric analysis of the TRANSIT quality indicators for cardiovascular disease prevention in primary care.

Khanji C, Bareil C, Hudon E, Goudreau J, Duhamel F, Lussier MT, Perreault S, Lalonde G, Turcotte A, Berbiche D, Martin É, Lévesque L, Gagnon MM, Lalonde L.

Int J Qual Health Care. 2017 Dec 1;29(8):999-1005. doi: 10.1093/intqhc/mzx145.

PMID:
29190350
5.

Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study.

Alkerwi A, Pagny S, Lair ML, Delagardelle C, Beissel J.

PLoS One. 2013;8(3):e57920. doi: 10.1371/journal.pone.0057920. Epub 2013 Mar 4.

6.

The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.

Hoerger TJ, Ahmann AJ.

J Manag Care Pharm. 2008 Feb;14(1 Suppl C):S2-14; quiz 15-6. Review.

PMID:
18240890
7.

Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.

Figliuzzi I, Presta V, Citoni B, Miceli F, Simonelli F, Battistoni A, Coluccia R, Ferrucci A, Volpe M, Tocci G.

Clin Cardiol. 2018 Jun;41(6):788-796. doi: 10.1002/clc.22955. Epub 2018 Jun 5.

8.

Management Status of Cardiovascular Disease Risk Factors for Dyslipidemia among Korean Adults.

Lee J, Son H, Ryu OH.

Yonsei Med J. 2017 Mar;58(2):326-338. doi: 10.3349/ymj.2017.58.2.326.

9.

Maintenance of Clinical Endpoints After Discharge from a Pharmacist-Managed Risk Reduction Clinic at a Veterans Affairs Medical Center.

Sherrill CH, Pentecost A, Wood EE.

J Manag Care Spec Pharm. 2016 Jan;22(1):14-20. doi: 10.18553/jmcp.2016.22.1.14.

10.

Therapeutic goal attainment in patients with hypertension and dyslipidemia.

Johnson ML, Pietz K, Battleman DS, Beyth RJ.

Med Care. 2006 Jan;44(1):39-46.

PMID:
16365611
11.

Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain.

Etxeberria A, Alcorta I, Pérez I, Emparanza JI, Ruiz de Velasco E, Iglesias MT, Rotaeche R.

BMC Health Serv Res. 2018 Feb 8;18(1):93. doi: 10.1186/s12913-018-2863-x.

12.

Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study.

Weiler S, Gemperli A, Collet TH, Bauer DC, Zimmerli L, Cornuz J, Battegay E, Gaspoz JM, Kerr EA, Aujesky D, Rodondi N.

BMC Health Serv Res. 2014 Jul 15;14:306. doi: 10.1186/1472-6963-14-306.

13.

Lifestyle changes for prehypertension with other cardiovascular risk factors: findings from Thailand.

Pongwecharak J, Treeranurat T.

J Am Pharm Assoc (2003). 2011 Nov-Dec;51(6):719-26. doi: 10.1331/JAPhA.2011.10129.

PMID:
22068193
14.

[Assessment of electronic medical records. Relationship between process indicators measured using electronic records and intermediate health outcomes in patients with hypertension].

Garzón González G, Rodríguez Morales D, Rodríguez Palomino MÁ, Toledo Gómez D, Hernández Barrera V, Gil De Miguel A.

Aten Primaria. 2012 Dec;44(12):709-19. doi: 10.1016/j.aprim.2012.06.004. Epub 2012 Sep 13. Spanish.

15.

Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?

Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P.

PLoS One. 2013 Oct 30;8(10):e78821. doi: 10.1371/journal.pone.0078821. eCollection 2013.

16.

Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance Using Cardiovascular Quality Indicators.

Barber CE, Esdaile JM, Martin LO, Faris P, Barnabe C, Guo S, Lopatina E, Marshall DA.

J Rheumatol. 2016 Nov;43(11):1965-1973. Epub 2016 Aug 1.

PMID:
27481908
18.

Cardiovascular risk management in diabetes in primary care.

Kalra S, Gupta Y.

J Pak Med Assoc. 2015 Aug;65(8):907-8.

19.

Accuracy of anthropometric indicators of obesity to predict cardiovascular risk.

Schneider HJ, Glaesmer H, Klotsche J, Böhler S, Lehnert H, Zeiher AM, März W, Pittrow D, Stalla GK, Wittchen HU; DETECT Study Group.

J Clin Endocrinol Metab. 2007 Feb;92(2):589-94. Epub 2006 Nov 14.

PMID:
17105840
20.

The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial.

Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR.

J Am Coll Cardiol. 2016 Jun 21;67(24):2846-54. doi: 10.1016/j.jacc.2016.03.528. Epub 2016 Apr 4.

Supplemental Content

Support Center